儿童甲状腺肿瘤中的 NTRK 融合：现状与未来展望。
NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives.
机构信息
Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, 816-C, Philadelphia, PA 19104, United States.
Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, United States; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
出版信息
Cancer Genet. 2022 Jun;264-265:23-28. doi: 10.1016/j.cancergen.2022.02.009. Epub 2022 Mar 6.
Pediatric and adult papillary thyroid cancer (PTC) share many similar oncogenic drivers, but differ in the pathological features and outcomes of the disease. The most frequent genetic alterations in adult PTCs are mutually exclusive point mutations in BRAF or the RAS family. In pediatric PTC, fusion oncogenes involving chromosomal translocations in tyrosine kinase (TK) receptors, most commonly RET and NTRK, are the most common genetic alterations observed. This review of the literature describes the current state of translational research in pediatric NTRK-driven thyroid cancer and highlights opportunities to improve our understanding and current models of pediatric PTC.
儿科和成人甲状腺乳头状癌 (PTC) 具有许多相似的致癌驱动因素，但在疾病的病理特征和结局方面有所不同。成人 PTC 中最常见的遗传改变是 BRAF 或 RAS 家族的互斥点突变。在儿科 PTC 中，涉及酪氨酸激酶 (TK) 受体的染色体易位的融合癌基因，最常见的是 RET 和 NTRK，是观察到的最常见的遗传改变。本文对儿科 NTRK 驱动的甲状腺癌的转化研究现状进行了综述，并强调了改善我们对儿科 PTC 的理解和现有模型的机会。
Zotero 插件